Group 1 - The core viewpoint of the news is that Tai Long Pharmaceutical has shown a significant increase in trading activity, with a 2.69% rise in stock price and a trading volume of 188 million yuan on January 23 [1] - As of January 23, the financing balance of Tai Long Pharmaceutical reached 290 million yuan, accounting for 7.35% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company has a diverse revenue structure, with 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [1] Group 2 - As of September 30, the number of shareholders for Tai Long Pharmaceutical was 40,400, a decrease of 1.08% from the previous period, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] - For the period from January to September 2025, Tai Long Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [2] - The company has distributed a total of 120 million yuan in dividends since its A-share listing, with 23.27 million yuan distributed over the past three years [3]

Core Viewpoint - The company has signed a maximum guarantee contract with China Everbright Bank to provide a joint liability guarantee for its subsidiary, Zhengzhou Deep Blue Marine Pharmaceutical Technology Co., Ltd., with a maximum principal amount of RMB 3 million [1][3]. Group 1: Guarantee Details - The guarantee is intended to support the operational development of the subsidiary, Deep Blue Marine, and is part of a comprehensive credit agreement valid from January 9, 2026, to January 8, 2027 [1][3]. - The company has approved a total guarantee limit of up to RMB 43 million for its subsidiaries for the year 2025, which can be adjusted internally based on actual operational needs [1][2]. - The guarantee covers all debts, including principal, interest, penalties, and other related costs incurred under the comprehensive credit agreement [3]. Group 2: Internal Decision-Making Process - The board of directors approved the guarantee proposal during meetings held on April 7, 2025, and April 29, 2025, ensuring compliance with internal approval procedures [1][4]. - The board believes that the guarantee will enhance financing efficiency and reduce costs, aligning with the company's operational needs and overall development strategy [4]. Group 3: Financial Position and Risk Assessment - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 297.03 million, representing 18.86% of the latest audited net assets [5]. - The company has not provided guarantees for controlling shareholders or related parties and has not experienced any overdue guarantees [5].

Group 1 - The core point of the article is that Tailong Pharmaceutical (stock code: 600222) announced a total external guarantee amount of 297.03 million yuan, which accounts for 18.86% of the most recent audited net assets, with no overdue guarantees reported [1] Group 2 - The total external guarantee amount includes the current announcement [1] - The percentage of the guarantee relative to the net assets indicates a significant level of financial commitment by the company [1] - The absence of overdue guarantees suggests a stable financial position regarding its obligations [1]

证券代码：600222 证券简称：太龙药业 公告编号：2026-003 河南太龙药业股份有限公司 关于为下属控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（含本次 | | 是否在前期预计 额度内 | 本次担保是否 有反担保 | | --- | --- | --- | --- | --- | --- | | | | 担保金额） | | | | | 郑州深蓝海生物医 药科技有限公司 | 300 万元 | 300 | 万元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 29,703.37（含本次） | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 18.86 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 | ...

Core Viewpoint - The company has approved a profit distribution plan at the fourth extraordinary general meeting of shareholders on November 14, 2025, which includes a cash dividend distribution for the first three quarters of 2025 [1]. Distribution Plan - The distribution is based on a total share capital of 573,886,283 shares, with 20,961,800 shares in the company's repurchase account excluded, resulting in a base of 552,924,483 shares for the cash dividend distribution of 0.14 yuan per 10 shares (including tax), totaling 7,740,942.76 yuan (including tax) [2]. - The cash dividend per share is calculated to be approximately 0.0135 yuan after adjusting for the total share capital [2][4]. - The company will only distribute cash dividends without issuing new shares or capital reserve transfers, meaning there will be no change in the circulating shares [2]. Relevant Dates - The cash dividend distribution will be executed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch, with shareholders able to receive their dividends on the designated payment date [5]. Taxation Information - For individual shareholders holding unrestricted circulating shares, the tax treatment varies based on the holding period, with a maximum tax rate of 20% for shares held for one month or less, and a reduced rate of 10% for shares held between one month and one year [6]. - For Qualified Foreign Institutional Investors (QFII), a 10% corporate income tax will be withheld, resulting in a net cash dividend of 0.0126 yuan per share [7]. - Other institutional investors are responsible for their own tax obligations, with a cash dividend of 0.014 yuan per share [7].

证券代码：600222 证券简称：太龙药业 公告编号：临 2026-002 河南太龙药业股份有限公司 统一社会信用代码：91410000706786295N 分类码：AhztChDh 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）近日收到河南 省药品监督管理局换发的《药品生产许可证》，同时对生产范围、生 产线及受托情况进行了变更，换发后的《药品生产许可证》有效期至 2030 年 12 月 31 日，现将相关情况公告如下： 一、换发后的《药品生产许可证》的相关情况 企业名称：河南太龙药业股份有限公司 许可证编号：豫 20150080 企业负责人：苏风山 住所（经营场所）：郑州高新技术产业开发区金梭路 8 号 法定代表人：王荣涛 质量负责人：李江华 生产负责人：张立壮 质量授权人：李江华 有效期至：2030 年 12 月 31 日 生产地址和生产范围： 证券代码：600222 证券简称：太龙药业 公告编号：临 2026-002 郑州高新技术产业开发 ...

Core Viewpoint - The company has received a renewed "Drug Production License" from the Henan Provincial Drug Administration, valid until December 31, 2030, which includes changes in production scope, production lines, and entrusted production situations [1] Group 1 - The renewal of the license ensures the company's normal operations and does not significantly impact the existing production structure [1] - The company will need to apply for GMP compliance checks to resume the production of certain products [1] - There are reductions in the production lines for certain products, including the reduction of the production of three drugs, such as Berberine Hydrochloride Tablets [1] Group 2 - The current changes do not affect the company's performance for this period, but there is uncertainty regarding drug production and sales due to policy and market influences [1]

证券代码：600222 证券简称：太龙药业 公告编号：2026-001 河南太龙药业股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.014元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2026/1/8 | － | 2026/1/9 | 2026/1/9 | 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 （1）本次差异化分红方案 公司以实施权益分派股权登记日登记的总股本 573,886,283 股，扣减公司回购专用证券 账户中的 20,961,800 股，即 552,924,483 股为基数，向全体股东每 10 股派发现金红利 0.14 元（含税），共计派发现金红利 7,740,942.76 元（含税）。 （2）本次差异化分红除权除息的计算依据 根据《上海证券交易所交易规则》，公司按 ...

Group 1 - The core point of the article is that Tailong Pharmaceutical (600222.SH) announced a cash dividend distribution plan for the first three quarters of 2025, with a total cash dividend of 0.14 yuan per 10 shares, amounting to a total distribution of 7,740,942.76 yuan (including tax) [1] - The total share capital for the dividend distribution is 573,886,283 shares, from which 20,961,800 shares held in the company's repurchase account are deducted, resulting in a base of 552,924,483 shares for the distribution [1] - The record date for the dividend distribution is set for January 8, 2026, and the ex-dividend date is January 9, 2026 [1]

仟问律师事务所 CHAINWINLAWFIRM 关于河南太龙药业股份有限公司 差异化分红事项的 专项法律意见书 仟见字【2025】591 号 二〇二五年十一月 中国·河南 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 河南仟问律师事务所 专项法律意见书 仟 问 律 师 事 务 所 5F,12F,Huanhu International Plaza,189#Ping'an Ave,Zhengdong District,Zhengzhou CHAINWINLAWFIRM 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 5F,12F,Huanhu International Plaza,189#Ping'an Ave,Zhengdong District,Zhengzhou 网址(URL)：http://www.chainwinlaw.com 电邮(E-mail):qwlss@126.com 仟见字【2025】第591号 河南仟问律师事务所 关于河南太龙药业股份有限公司差异化分红事项的 专项法律意见书 致：河南太龙药业股份有限公司 河南仟问律师事务所接受河南太龙 ...